<DOC>
	<DOCNO>NCT00965458</DOCNO>
	<brief_summary>The purpose trial test whether drug call alefacept slow halt destruction beta cell pancreas . If destruction beta cell stop , patient might able produce insulin long , could stop slow progression type 1 diabetes . This multi-center prospective , placebo-controlled , double-blind randomize trial investigate ability alefacept protect residual beta cell ongoing autoimmune destruction adolescent young adult newly diagnose Type 1 Diabetes Mellitus ( T1DM ) .</brief_summary>
	<brief_title>Inducing Remission Type 1 Diabetes With Alefacept</brief_title>
	<detailed_description>T1DM autoimmune disease emerge suddenly , cause dependence insulin life . This mean immune system ( part body help fight infection ) mistakenly attack cell pancreas produce insulin ( beta cell ) . As beta cell destroy , one 's ability produce insulin decrease . Insulin help keep blood glucose ( sugar ) level normal . For period right diagnosis , pancreas still able make small amount insulin . Individuals diabetes ability produce insulin may able achieve good blood sugar control people produce insulin . Based previous research , doctor think give medicine affect immune system soon diagnosis may stop , delay , decrease destruction beta cell , result good glucose control . This help prevent secondary complication diabetes road . Research improve outlook T1DM last decade . Doctors investigate , example , save insulin-producing cell extend honeymoon period long possible . Despite progress towards understand science behind T1DM , remain significant need investigate alternative approach disease order bring long-term remission . For reason , scientist work hard develop new treatment give soon diagnosis preserve remain beta cell . Currently cure T1DM ; however , new investigational medication innovative clinical research study , T1DAL , new approach towards manage T1DM may horizon . Enrollees receive weekly intramuscular injection alefacept placebo two 12 week period , 12-week pause treatment interval . This schedule drug dosing may alter due need subject discretion physician investigator .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Recent diagnosis ( within 100 day enrollment ) T1DM Positive least one diabetes autoantibody ( Glutamate decarboxylase [ GAD65GAD65 ] , IA2 , ZnT8 , ICA Insulin , obtain within 10 day onset exogenous insulin therapy ) Peak stimulate Cpeptide level &gt; 0.2 pmol/mL follow mixedmeal tolerance test ( MMTT ) Willingness provide write informed consent ( either subject subject 's legally authorize representative ) . Severe reaction anaphylaxis human monoclonal antibody History malignancy significant cardiovascular disease ( include history myocardial infarction , angina , use antianginal medicine ( e.g. , nitroglycerin ) , abnormal stress test ) History recent ongoing uncontrolled bacterial , viral , fungal , opportunistic infection Evidence infection hepatitis B virus ( HBV ) define hepatitis B surface antigen , HBsAg ; hepatitis C virus ( HCV ) define antiHCV antibody ; human immunodeficiency virus ( HIV ) ; toxoplasmosis Positive tuberculin skin test ( PPD ) Clinically active infection EpsteinBarr virus ( EBV ) EBV viral load ≥ 10,000 copy per 10^6 PBMCs ; cytomegalovirus ( CMV ) CMV viral load ≥10,000 copy per mL whole blood ; tuberculosis ( TB ) Diagnosis liver disease hepatic enzyme , define ALT and/or AST ≥ 2 time upper limit normal Prior current treatment know cause significant , ongoing change course T1DM immunologic status , include highdose inhale , extensive topical systemic glucocorticoid Current prior ( within last 30 day ) use metformin , sulfonylurea , glinides , thiazolidinediones , exenatide , liraglutide , DPPIV inhibitor amylin Current use medication know influence glucose tolerance ( e.g. , atypical antipsychotic , diphenylhydantoin , thiazide , potassiumdepleting diuretic , βadrenergic blocker , niacin ) Any follow hematologic abnormality , confirm repeat test least 1 week apart : 1 . White blood count &lt; 4000/μL &gt; 14,000/μL ; 2 . CD4+ count lower limit normal ; 3 . Platelet count &lt; 150,000 /μL ; 4 . Hemoglobin &lt; 10 g/dL . Females pregnant , lactating , plan pregnancy 2year study period History bone marrow transplantation , autoimmune disease associate lymphopenia Any medical condition opinion principal investigator would interfere safe completion trial Prior participation clinical trial could potentially affect T1DM immunologic status Receipt live vaccine ( e.g. , varicella , measles , mumps , rubella , coldattenuated intranasal influenza vaccine , bacillus CalmetteGuérin , smallpox ) 6 week enrollment Participation investigational clinical trial within last six week .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>New-onset Type 1 Diabetes Mellitus</keyword>
	<keyword>New-onset T1DM</keyword>
	<keyword>New-onset T1D</keyword>
	<keyword>Alefacept</keyword>
	<keyword>Amevive®</keyword>
</DOC>